

Appendix 2: 2017-18 Licensed Influenza Vaccines

Product characteristics	Injectable								Intranasal
Manufacturer	BGP Pharma	GSK		Novartis			Sanofi Pasteur		AstraZeneca
Product name	Influvac®	Fluviral®	FluLaval® Tetra	Agriflu®	Fluad®	Fluad Pediatric™	Fluzone® High-Dose	Fluzone® Quadrivalent	FluMist® Quadrivalent †
Vaccine type	Trivalent inactivated - subunit	Trivalent inactivated - split virus	Quadrivalent inactivated - split virus	Trivalent inactivated - subunit	Trivalent inactivated - subunit	Trivalent inactivated - subunit	Trivalent inactivated - split virus	Quadrivalent inactivated - split virus	Quadrivalent Live attenuated
Route	IM	IM	IM	IM	IM	IM	IM	IM	IN
Authorized ages	≥ 3 years	≥ 6 months	≥ 6 months	≥ 6 months	≥ 65 years	6-23 months	≥ 65 years	≥ 6 months	2-59 years
Adjuvant	No	No	No	No	MF ₅₉	MF ₅₉	No	No	No
MDV Post-puncture shelf life	Refer to product monograph	Refer to product monograph	28 days	Refer to product monograph	Refer to product monograph	Refer to product monograph	Refer to product monograph	May be used up to the expiry date indicated on the vial	n/a
Thimerosal	Refer to product monograph	Refer to product monograph	Yes	Refer to product monograph	Refer to product monograph	Refer to product monograph	Refer to product monograph	Multidose vials only	No
Antibiotics	Refer to product monograph	Refer to product monograph	None	Refer to product monograph	Refer to product monograph	Refer to product monograph	Refer to product monograph	None	Gentamicin
Clinically non-relevant ingredients*	Refer to product monograph	Refer to product monograph	Appendix 1: 2017-18 Publicly Funded Influenza Vaccine Information	Refer to product monograph	Refer to product monograph	Refer to product monograph	Refer to product monograph	Appendix 1: 2017-18 Publicly Funded Influenza Vaccine Information	Refer to product monograph